Investigation of relationship of serous ovarian tumors with MDM2, WWP1 and parc molecules that responsible intracellular localization of P53

Serous ovarian cancer is the most common cause of death due to gynecological malignancies. Molecular pathologically, serous ovarian cancers are examined in two categories according to their p53 mutation status. While high-grade serous carcinomas carry p53 mutation, the p53 mutation is not observed in low-grade serous carcinomas. P53 mutation is evaluated immunohistochemically and there are different types of mutations according to the cellular localization of p53. The cellular localization and activity of p53 are controlled by E3 ubiquitin ligases. In our study, it was thought that the different cellular localizations of mutant p53 observed in high-grade serous carcinomas may be regulated by MDM2, WWP1 and PARC, which are E3 ubiquitin ligases. The immunohistochemical findings of MDM2, PARC and WWP1 in 7 low-grade serous carcinomas, 38 high-grade serous carcinomsa, 15 serous cystadenomas, p53 status, other histopathological and clinical data belonging to the 2011 – 2019 year archive of the Karadeniz Technical University Medical Pathology Department were compared. As a result of our study, it is seen that PARC and WWP1 show loss of expression in serous ovarian cancer. This loss increases as the degree of malignancy increases and becomes more prominent in high-grade serous ovarian carcinoma. MDM2 expression showed no significant difference. A study in which WWP1 and PARC were compared with p53 expression patterns in serous ovarian cancer was not found in the literature. When the roles of WWP1 and PARC in ovarian cancer and their relationship with p53 are better clarified, they can be used in the targeted treatment of especially high-grade serous ovarian cancer.